21 news items
Oppenheimer Maintains Outperform on Sutro Biopharma, Maintains $10 Price Target
STRO
15 May 24
Oppenheimer analyst Jay Olson maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $10 price target.
Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $8 Price Target
STRO
14 May 24
Wedbush analyst David Nierengarten reiterates Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $8 price target.
HC Wainwright & Co. Reiterates Buy on Sutro Biopharma, Maintains $12 Price Target
STRO
14 May 24
HC Wainwright & Co. analyst Andrew Fein reiterates Sutro Biopharma (NASDAQ:STRO) with a Buy and maintains $12 price target.
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
STRO
13 May 24
Milestones Luveltamab Tazevibulin (luvelta), FolRα-Targeting ADC Franchise
Expert Outlook: Sutro Biopharma Through The Eyes Of 10 Analysts
STRO
8 May 24
Insights from analysts' 12-month price targets are revealed, presenting an average target of $12.5, a high estimate
frm8vvxfom5cc25h1aogwhtixr4m6bsji6ukeif
STRO
8 May 24
B of A Securities analyst Tazeen Ahmad initiates coverage on Sutro Biopharma (NASDAQ:STRO) with a Buy rating and announces Price Target of $12.
wo9tuj95piwn3z58hh6g8c0o5jiv1vebmrg49kw0csc7ho8pd5h
STRO
3 Apr 24
Piper Sandler analyst Edward Tenthoff reiterates Sutro Biopharma (NASDAQ:STRO) with a Overweight and lowers the price target from $12 to $11.
3nvt53ska1c5io 6bhh
STRO
3 Apr 24
Oppenheimer analyst Jay Olson maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $10 price target.
31jvzb3f5r4i8mp9gkfvrjhi1lu7u3i10k57wdy4t1wz cu1qzt6ragb
STRO
3 Apr 24
Truist Securities analyst Asthika Goonewardene maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and lowers the price target from $25 to $18.
1ljm3e3i4dkxoha2flkypuw4m7xndfvnad1pi2 kvg31e1m2u
STRO
3 Apr 24
JMP Securities analyst Reni Benjamin reiterates Sutro Biopharma (NASDAQ:STRO) with a Market Outperform and maintains $17 price target.
0qobyj9v90hh44a35dethhr4
STRO
2 Apr 24
, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline
ymth69yh27gcsbvfwjqsf
STRO
2 Apr 24
stages of pre-clinical development
STRO-003 targets ROR1, a clinically validated antibody drug conjugate (ADC) target
STRO-003 has
g2dt1i3v37zkzbgz2ompsxp0wq6y42z22rwgjmf1m3o
STRO
2 Apr 24
the final stages of pre-clinical developmentSTRO-003 targets ROR1
9keg29muclreo5p2qcdkas5e9by12nuboj4mv6asr
ABTS
AKAN
ALLG
28 Mar 24
a $10 price target.
Kintara Therapeutics, Inc
tj7h8w2ou5a3aez5rk93huyv6g1u
STRO
28 Mar 24
Oppenheimer analyst Jay Olson maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $10 price target.
ha9xtb3d83qrr0nwgz7w4qaufyo1yjlg9w6v0o4n5ntb3x2thibck5cjpvo
STRO
27 Mar 24
0
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target
2cke0wxeln4 gb8mjs8
STRO
27 Mar 24
Oppenheimer analyst Jay Olson maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $10 price target.
zt43wpavlgd95mcbh43je6i5ennvv4aalf474w14i2z4vc00l10jcegbw7y7
STRO
26 Mar 24
Wedbush analyst David Nierengarten maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and lowers the price target from $12 to $8.
qdpwcop23i2p4pvmsd4czgqx2exgzahtqkxz517cw mdzcf5gx8f17nxh
STRO
26 Mar 24
JMP Securities analyst Reni Benjamin reiterates Sutro Biopharma (NASDAQ:STRO) with a Market Outperform and maintains $17 price target.
30uqg
STRO
26 Mar 24
HC Wainwright & Co. analyst Andrew Fein maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and lowers the price target from $16 to $12.